规格 | 目录价格 | 上海 | 安徽 | 武汉 | 成都 | 北方 | 深圳 | 会员价格 | 数量 |
---|---|---|---|---|---|---|---|---|---|
1g | ¥ ôǕŧƌƌ | > 10 | > 10 | 1 | -- | 3 | 1 | ¥ ôǕŧƌƌ | - + |
5g | ¥ ǕNJŧƌƌ | 2 | > 10 | 2 | 5 | 8 | 4 | ¥ ǕNJŧƌƌ | - + |
10g | ¥ Ȁƿŧƌƌ | 1 | > 10 | -- | 2 | 5 | 1 | ¥ Ȁƿŧƌƌ | - + |
25g | ¥ ȏýƝŧƌƌ | -- | > 10 | -- | 3 | 5 | 2 | ¥ ȏýƝŧƌƌ | - + |
100g | ¥ ȀƝȏŧƌƌ | -- | > 10 | -- | 3 | 4 | 2 | ¥ ȀƝȏŧƌƌ | - + |
500g | ¥ ǕôƌƝŧƌƌ | -- | 3 | -- | -- | -- | -- | ¥ ǕôƌƝŧƌƌ | - + |
1kg | ¥ ȀƝýýŧƌƌ | -- | 1 | -- | -- | -- | -- | ¥ ȀƝýýŧƌƌ | - + |
大货 | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
产品编号
1053509
CAS 号
54-96-6
中文名称
3,4-二氨基吡啶
MDL 号
MFCD00006401
分子量
109.13
存储条件
Store at room temperature
网页展示纯度为入库指导纯度值,各批次间存在一定差异,实际纯度以收货为准
熔点
216-218°C
沸点
369.3°C at 760 mmHg
闪点
240°C
旋光
描述
TPSA
64.93
LogP
0.246
H_Acceptors
3
H_Donors
2
Rotatable_Bonds
0
[1]. Maarten J Titulaer, et al. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011 Dec;10(12):1098-107.
[2]. Ojala KS, et al. A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs. J Biol Chem. 2021 Jan-Jun;296:100302.
[3]. T L Harris, et al. Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication. Chem Commun (Camb). 2016 Mar 18;52(22):4187-90.
[4]. A Quartel, et al. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Curr Med Res Opin. 2010 Jun;26(6):1363-75.
[5]. Adrian Quartel, et al. Orphan drugs. BioMarin Europe replies. BMJ. 2010 Dec 7:341:c7006.
警示图
警示词
Danger
危险申明
H300+H330-H311-H319
警告申明
P260-P264-P270-P271-P280-P284-P302+P352-P304+P340-P330-P361+P364-P405-P501
GHS 编码
GHS06
危险类别
6.1
UN 编码
2811
包装等级
Ⅱ
展开更多
现货供应
专业护航
售后无忧
品质保障
无需凑单